Moreover, considering the clinical importance of excessive IL-1ß generation in a wide variety of thrombo-inflammatory disorders, as shown by the CANTOS trial (67, 68), PAD-dependent regulation of NLRP3 protein levels could be an important mechanism in inflammasome-driven diseases and makes PADs promising new targets in the therapy of cardiovascular diseases (15, 69, 70). Here, NLRP3 is linked to cardiovascular disorder.